Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Y-Biologics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Creation of a Research Partnership Between Pierre Fabre and Y-Biologics to Develop New Immunotherapies Based on Monoclonal Antibodies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Y-Biologics","sponsor":"3D Medicines","pharmaFlowCategory":"D","amount":"$87.0 million","upfrontCash":"$2.0 million","newsHeadline":"3D Medicines Signed License Agreement with Y-Biologics on the Co-development of Next-generation T Cell Bispecific Engager","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Y-Biologics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Y-Biologics and Pierre Fabre Sign an Exclusive License Agreement in the Field Of Immuno-Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Y-Biologics

    Menu

    Y-Biologics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Y-Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Y-Biologics and Pierre Fabre Sign an Exclusive License Agreement in the Field Of Immuno-Oncology

              Details:

              The agreement grants Pierre Fabre the worldwide exclusive rights to develop and commercialize a family of human antibodies generated through the phage display human antibody Ymax®-ABL library owned by Y-Biologics.

              Lead Product(s): Human Antibody-based Therapeutic

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Pierre Fabre

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement July 06, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Y-Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              3D Medicines Signed License Agreement with Y-Biologics on the Co-development of Next-generation T Cell Bispecific Engager

              Details:

              3D Medicines will obtain rights to develop, manufacture, and commercialize YBL-013, a T cell bi-specific engager based on ALiCE platform technology, in the Territory of Greater China (mainland China, Hong Kong, Macau and Taiwan) and will co-developed it across the globe.

              Lead Product(s): YBL-013,Envafolimab

              Therapeutic Area: Oncology Product Name: YBL-013

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: 3D Medicines

              Deal Size: $87.0 million Upfront Cash: $2.0 million

              Deal Type: Licensing Agreement January 05, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Y-Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Creation of a Research Partnership Between Pierre Fabre and Y-Biologics to Develop New Immunotherapies Based on Monoclonal Antibodies

              Details:

              Under the terms of this agreement, Y-Biologics will contribute through its human antibody display platforms to generate therapeutic and diagnostic monoclonal antibodies directed against key molecular targets designated by Pierre Fabre.

              Lead Product(s): Monoclonal antibodies

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: Pierre Fabre

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership November 23, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY